NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology
August 30 2016 - 7:00AM
Business Wire
NeuroMetrix, Inc. (NASDAQ:NURO) today announced the launch
of a new website to promote Quell®, the company’s rapidly growing
pain relief brand.
The new site reflects NeuroMetrix’ focus on helping people with
chronic pain reclaim their lives. The QuellRelief.com website
incorporates user-requested content such as:
- Compelling testimonials of the
real-world experiences of chronic pain sufferers using Quell
technology
- Enhanced clinical and scientific data
for healthcare professionals
- Improved content to support current
Quell users
- A retail finder to help locate one of
the 1,500 stores or online outlets selling Quell
“With over 100,000 visits to QuellRelief.com each month, we
designed the new site with the user experience in mind,” said Frank
McGillin, Senior Vice President and General Manager, Consumer.
“We’ve made it easier to explore the facts around chronic pain and
how Quell technology may help.”
About Quell Wearable Pain Relief Technology
Quell is FDA cleared and designed for the millions of people
suffering from chronic pain. The advanced wearable technology
delivers 100% drug free relief and is available without a
prescription. Quell can be used during the day while active and at
night while sleeping. Quell gives users the option to start, stop,
and adjust therapy discreetly via their smartphone. It also
provides therapy utilization and advanced sleep tracking. Quell is
available at select healthcare professionals and retailers. To find
a Quell retailer, visit the Store Locator at QuellRelief.com.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep
disorders, and diabetes. The company’s lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs, including a therapeutic device for restless leg syndrome.
The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health
Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160830005393/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial OfficerNeurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024